DOCSLIB.ORG

40 Compounded Formulations for Symptomatic Management Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
40 Compounded Formulations for Symptomatic Management Of Compounded formulations for symptomatic management of mucositis There are numerous magic mouthwash preparations. Most contain at least 3 ingredients. These may include an antibiotic to reduce bacterial flora around areas of mucosal breakdown, an antifungal to stop fungal growth, a local anesthetic/pain reliever, an antihistamine for local anesthetic effect, a steroid to reduce inflammation and an antacid to enhance coating of the ingredients in the mouth.4 Note that nystatin has not been shown to be effective in treating oral fungal infections associated with oral mucositis.5 Most formulations are used every 4-6 hours prn with instructions to hold in the mouth for 1-2 minutes then spit out or swallow. Patients should be instructed not to eat or drink for 30 minutes after use. Seattle Mouth Wash Recipe: Dosage Instructions: (shake well) Maalox 200 ml Adult: 15-30 ml q4h prn Lidocaine 2% Viscous 100 ml Children: 2.5-5 ml (up to 10 ml) Diphenhydramine 12.5 mg/5ml elixir 200 ml may be swallowed, use caution if (expiry date 6 months) giving food within 60 minutes BC Cancer Agency Magic Mouth Wash Recipe: Dosage Instructions: (shake well) Diphenhydramine 12.5mg/5ml elixir 150 ml Adult: 15-30 ml swish and rinse Nystatin 100,000 U/ml susp. 36 ml or swallow q3-4 h. prn Hydrocortisone 100 mg/2ml inj vial 1 ml Sterile water for irrigation 313 ml (refrigerate, expiry date 30 days) Pink Lady Recipe: Dosage Instructions: 2 parts Maalox/Diovol (200 ml) 15 ml q4h prn 1 part Viscous Lidocaine 2% (100 ml) best 20 minutes prior to meals (expiry date 30 days) Other medications for mucositis: Benzydamine (Tantum oral rinse) 15 ml held for at least 30 seconds then expelled qid prn (contains 10% ethanol so may sting or burn – may be avoided by diluting with equal parts of lukewarm water prior to use) 4 Magic Mouthwash. Pharmacist’s Letter/Prescriber’s Letter 2007;23(7):230703 5 Chan A, Ignoffo RJ. Survey of topical oral solutions for the treatment of chemo-induced oral mucositis. J.Oncol Pharm Practice 2005; 11:139-143. 40.
Load more

Recommended publications
  • 2021 SELECT EX FORMULARY the Following Is a List of the Most Commonly Prescribed Brand and Generic Medications
    2021 SELECT EX FORMULARY The following is a list of the most commonly prescribed brand and generic medications. It represents an abbreviated version of the formulary list that is at the core of your prescription drug benefit plan. The list is not all-inclusive and does not guarantee coverage. Some preferred medications overlap with other clinical programs and may not be covered. In addition to drugs on this list, the majority of generic medications are covered under your plan and you are encouraged to ask your doctor to prescribe generic drugs whenever appropriate. Search complete formulary drug information at elixirsolutions.com. PLEASE NOTE: Preferred brand drugs may move to non-preferred status if a generic version becomes available during the year. Any medication approved to enter the market will not be covered until reviewed by Elixir. Not all drugs listed are covered by all prescription drug benefit programs. For specific questions about your coverage, please visit elixirsolutions.com. A B CILOXAN OINTMENT digoxin abacavir tablet balsalazide CIMDUO diltiazem ER (except generics for abacavir-lamivudine BAQSIMI cinacalcet CARDIZEM LA) ABILIFY MAINTENA [INJ] BASAGLAR [INJ] ciprofloxacin dimethyl fumarate DR* abiraterone* BD ULTRAFINE INSULIN SYRINGES ciprofloxacin-dexamethasone diphenoxylate-atropine acetic acid & NEEDLES citalopram dipyridamole ER-aspirin acitretin BELBUCA CITRANATAL divalproex sodium ACUVAIL BELSOMRA clarithromycin divalproex sodium ER acyclovir capsule, tablet benzonatate (except NDCs: clarithromycin ER DIVIGEL
    [Show full text]
  • Topical Therapy As a Treatmentfor Brachioradial
    Journal of Case Reports: Open Access Case report Open Access Topical Therapy as a Treatmentfor Brachioradial Pruritis: a Case Report Brianna De Souza M.D, Amy McMichael M.D* Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina *Corresponding author: Amy McMichael, MD Department of Dermatology, Wake Forest Baptist Medical Center,1 Medical Center Blvd, Winston-Salem, NC 27157, Phone: 336-716-7882, Email: [email protected] Received Date: April 12, 2019 Accepted Date: May 06, 2019 Published Date: May 08, 2019 Citation: Brianna De Souza (2019) Topical Therapy as a Treatmentfor Brachioradial Pruritis: a Case Report. Case Reports: Open Access 4: 1-5. Abstract Management of brachioradial pruritus (BRP) presents a formidable challenge to dermatologists and neurologists. BRP is a rare, neurocutaneous condition characterized by sharply localized, chronic pain with associated itching, burning, stinging, and or tingling sensation. Effective care of this patient population is confounded by limitations within the litera- ture, comprised of case series and case reports. We present a case of one middle-aged female with a chronic history of BRP recalcitrant to the following oral therapies: pregabalin, gabapentin, mirtazapine, prednisone, and amitriptyline, as well as topical triamcinolone. After being evaluated in the clinic, the patient was started on combination therapy withKetamine 10%, Amitriptyline 5%, and Lidocaine 5% topical cream to which she responded. Keywords: Brachioradial pruritus, Brachioradial, Pruritus, Neurocutaneous ©2019 The Authors. Published by the JScholar under the terms of the Crea- tive Commons Attribution License http://creativecommons.org/licenses/ by/3.0/, which permits unrestricted use, provided the original author and source are credited.
    [Show full text]
  • Antagonism of Lidocaine Inhibition by Open-Channel Blockers That Generate Resurgent Na Current
    4976 • The Journal of Neuroscience, March 13, 2013 • 33(11):4976–4987 Cellular/Molecular Antagonism of Lidocaine Inhibition by Open-Channel Blockers That Generate Resurgent Na Current Jason S. Bant,1,3 Teresa K. Aman,2,3 and Indira M. Raman1,2,3 1Interdepartmental Biological Sciences Program, 2Northwestern University Interdepartmental Neuroscience Program, and 3Department of Neurobiology, Northwestern University, Evanston, Illinois 60208 Na channels that generate resurgent current express an intracellular endogenous open-channel blocking protein, whose rapid binding upon depolarization and unbinding upon repolarization minimizes fast and slow inactivation. Na channels also bind exogenous com- pounds, such as lidocaine, which functionally stabilize inactivation. Like the endogenous blocking protein, these use-dependent inhibi- tors bind most effectively at depolarized potentials, raising the question of how lidocaine-like compounds affect neurons with resurgent Na current. We therefore recorded lidocaine inhibition of voltage-clamped, tetrodotoxin-sensitive Na currents in mouse Purkinje neu- rons, which express a native blocking protein, and in mouse hippocampal CA3 pyramidal neurons with and without a peptide from the ␤ ␤ cytoplasmic tail of NaV 4 (the 4 peptide), which mimics endogenous open-channel block. To control channel states during drug exposure, lidocaine was applied with rapid-solution exchange techniques during steps to specific voltages. Inhibition of Na currents by lidocaine was diminished by either the ␤4 peptide or the native blocking protein. In peptide-free CA3 cells, prolonging channel opening with a site-3 toxin, anemone toxin II, reduced lidocaine inhibition; this effect was largely occluded by open-channel blockers, suggesting that lidocaine binding is favored by inactivation but prevented by open-channel block.
    [Show full text]
  • Amitriptyline Hydrochloride 2%, Gabapentin 6%, Lidocaine Hydrochloride 0.5% FIN F 008 269 Formula Oral Mucoadhesive Rinse (Solution, 100 Ml)
    MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 [email protected] 4/7/2020; Page 1 Suggested Amitriptyline Hydrochloride 2%, Gabapentin 6%, Lidocaine Hydrochloride 0.5% FIN F 008 269 Formula Oral Mucoadhesive Rinse (Solution, 100 mL) SUGGESTED FORMULATION Lot Expiry Ingredient Listing Qty. Unit NDC # Supplier Number Date Amitriptyline Hydrochloride, USP 2.000 g Gabapentin, USP 6.000 g Lidocaine Hydrochloride, USP TBD Potassium Sorbate, NF 0.10 g Stevia Powder 0.10 g Menthol (Crystals) (Levorotatory) 0.02 g (Natural), USP Alcohol (95%), USP 5.0 mL NovaFilm™ 30.0 mL Purified Water, USP 50.0 mL Purified Water, USP q.s. to 100.0 mL Sodium Hydroxide 10% Solution As required MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 [email protected] 4/7/2020; Page 2 Suggested Amitriptyline Hydrochloride 2%, Gabapentin 6%, Lidocaine Hydrochloride 0.5% FIN F 008 269 Formula Oral Mucoadhesive Rinse (Solution, 100 mL) SPECIAL PREPARATORY CONSIDERATIONS Ingredient-Specific Information Light Sensitive (protect from light whenever possible): Amitriptyline Hydrochloride, Gabapentin Hygroscopic (protect from moisture whenever possible): Stevia Powder Narrow Therapeutic Index Lidocaine Hydrochloride Suggested Preparatory Guidelines ■ Non-Sterile Preparation □ Sterile Preparation Processing Error / To account for processing error and pH testing considerations during preparation, it is Testing Considerations: suggested to measure an additional 3 to 5% of the required quantities of ingredients. Special Instruction: This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016.
    [Show full text]
  • The Effects of Lidocaine and Mefenamic Acid on Post-Episiotomy
    Shiraz E-Med J. 2016 March; 17(3):e36286. doi: 10.17795/semj36286. Published online 2016 March 27. Research Article The Effects of Lidocaine and Mefenamic Acid on Post-Episiotomy Pain: A Comparative Study Masoumeh Delaram,1,* Lobat Jafar Zadeh,2 and Sahand Shams3 1Faculty of Nursing and Midwifery, Shahrekord University of Medical Sciences, Shahrekord, IR Iran 2Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, IR Iran 3Faculty of Veterinary Medicine, Shahrekord University, Shahrekord, IR Iran *Corresponding author: Masoumeh Delaram, Faculty of Nursing and Midwifery, Shahrekord University of Medical Sciences, Shahrekord, IR Iran. Tel: +98-3813335648, Fax: +98-3813346714, E-mail: [email protected] Received 2016 January 13; Revised 2016 February 29; Accepted 2016 March 04. Abstract Background: Most women suffer pain following an episiotomy and oral non-steroidal anti-inflammatory drugs are commonly used for pain relief. Due to the gastrointestinal side effects of oral drugs, it seems that women are more accepting of topical medications for pain relief. Objectives: Therefore, the aim of this study was to compare the effects of lidocaine and mefenamic acid on post-episiotomy pain. Patients and Methods: This clinical trial was carried out in 2011. It involved sixty women with singleton pregnancy who were given an episiotomy at 38 to 42 weeks of gestation. The participants were randomly divided into two groups. One group received 2% lido- caine cream (n = 30), while the other group received 250 mg of mefenamic acid (n = 30). The data were collected via a questionnaire and a visual analog scale. Pain intensity was compared from the first complaint by the mother and at 6, 12, and 24 hours after the delivery in both groups.
    [Show full text]
  • A Concise Guide to Treating Painful Oral Lesions
    Drugs Used to Treat Osteoporosis and Bone Cancer Perio & Implant Centers The Team for of the Monterey Bay (831) 648-8800 Jochen P. Pechak, DDS, MSD in Silicon Valley (408) 738-3423 Which May Cause Osteonecrosis of the Jaws mobile: www.DrPechakapp.com he many bisphosphonates and monoclonal antibodies which are used to treat osteoporosis and bone cancer often web: GumsRus.com causeDrugsDrugs osteonecrosis Used Used of the to jaws.to Treat AsTreat dental clinicians,Osteoporosis Osteoporosis it is important that and andwe are Bone awareBone of this Cancers Cancers side effect before Ttreating our patients who are taking these drugs. The tables below summarize these drugs, the route these drugs are administered, andWhich Whichtheir likelihood May May of causing Cause Cause osteonecrosis Osteonecrosis Osteonecrosis of the jaws as reported byof of Dr. the theRobert Jaws JawsMarx at the University of Miami Division of Oral and Maxillofacial Surgery. PDL tm Osteoporosis Drugs Drugs Osteoporosis Used to Treat Drugs Osteoporosis PerioDontaLetter Jochen P. Pechak, DDS, MSD, Periodontics and Implant Dentistry Spring DrugDrug ClassificationClassification ActionAction DoseDose RouteRoute %% of of ReportedReported CasesCases of of OsteonecrosisOsteonecrosis AlendronateAlendronate BisphosphonateBisphosphonate OsteoclastOsteoclast 7070 mg/wk mg/wk OralOral 8282%% From Our Office A Concise Guide to Treating (Fosamax(Fosamax ToxicityToxicity to Yours... Generic)Generic) Painful Oral Lesions ResidronateResidronate BisphosphonateBisphosphonate OsteoclastOsteoclast 3535 mg/wk mg/wk OralOral 1%1% As dentists specializing in treat- (Actonel Toxicity (Actonel Toxicity ment of diseases of the oral cavity atients present frequently with Treating Cold Sores Atelvia)Atelvia) and associated structures, we are painful oral lesions. They are often also called upon to treat pain- IbandronateIbandronate BisphosphonateBisphosphonate OsteoclastOsteoclast 150150 mg/mos mg/mos OralOral 1%1% usually not serious, but patients And Canker Sores (Boniva) Toxicity IV ful oral lesions in the mouth.
    [Show full text]
  • Making an Elderberry Syrup Or Elixir
    Making an Elderberry Syrup or Elixir Herbal syrups are water extractions of herbs (usually decoctions—see below) that are concentrated with a sweetener (preferably organic white sugar or raw honey). This sweetener provides a bit of nutritional support as a carbohydrate and also acts as a preservative. The concentration of sugar is particularly important when making syrups and elixirs; when in water, sugar acts as a food source for micro-organisms (especially molds and yeasts). However, at a high enough concentration, the sugar actually restricts the growth ability of micro-organisms. So we are aiming to get our syrup to be saturated enough to preserve, but not so saturated that the sugar overwhelms the liquid and causes crystallization. When preparing a syrup, one of the following ratios should be used: 1 part decoction : 1 part sweetener 1 part decoction : 2 parts sweetener I tend to follow the 1 part water : 1 part sweetener suggestion, as the 1 : 2 ratio is too sweet for me. But I have access to a refrigerator, which will also help with preservation. If you are keeping your syrup at room temperature, the 1:2 ratio is best. Syrups are a great, palatable method for delivery of herbal medicines (especially for children), and are also a great way to mask the flavor of less tasty tinctures--just combine the tincture and the syrup and you get the medicinal benefits of both. Preserving syrups with honey is also a great way to combine the medicinal benefits of the honey with the herbs that are being used. Do not give syrups preserved with honey to children under the age of one.
    [Show full text]
  • Fenestrations Control Resting-State Block of a Voltage-Gated Sodium
    Fenestrations control resting-state block of a voltage- gated sodium channel Tamer M. Gamal El-Dina,1, Michael J. Lenaeusa,b,1, Ning Zhenga,c,2,3, and William A. Catteralla,2,3 aDepartment of Pharmacology, University of Washington, Seattle, WA 98195; bDivision of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA 98195; and cHoward Hughes Medical Institute, University of Washington, Seattle, WA 98195 Contributed by William A. Catterall, October 31, 2018 (sent for review September 4, 2018; reviewed by Ryan Hibbs, Michael C. Sanguinetti, and Joerg Striessnig) Potency of drug action is usually determined by binding to a specific Receptor Hypothesis posits that resting-state block is mediated receptor site on target proteins. In contrast to this conventional by drug entry from the lipid phase of the membrane into the drug paradigm, we show here that potency of local anesthetics (LAs) and receptor site in the pore, and rapid open-state block occurs as the antiarrhythmic drugs (AADs) that block sodium channels is con- drug enters the open pore from the cytoplasm (15). Both of these trolled by fenestrations that allow drug access to the receptor site forms of block are enhanced when the channel enters the inac- directly from the membrane phase. Voltage-gated sodium channels tivated state, which has high affinity for bound drug (15). It is initiate action potentials in nerve and cardiac muscle, where their well-established that LAs and AADs can reach their binding site hyperactivity causes pain and cardiac arrhythmia, respectively. LAs from the intracellular side if the activation gate is open, which and AADs selectively block sodium channels in rapidly firing nerve gives open-state block, and that inactivation increases the affinity and muscle cells to relieve these conditions.
    [Show full text]
  • Slang Terms and Jargon Can Cause Medication Errors
    Volume 19, Number 10 November/December 2005 Drugs & Therapy B � U � L � L � E � T � I � N MEDICATION SAFETY FORMULARY UPDATE The Pharmacy and Therapeutics Slang terms and jargon can Committee met October 18, 2005. 4 products were added in the Formulary cause medication errors and 2 were deleted. 1 dosage form was evaluated and designated nonformu- his month “Magic Mouthwash” ents. An allergy screen would not be lary and not available, and 2 drugs T was deleted from the Formulary done, unless the individual ingredients were evaluated, but not added. Criteria (see Formulary Update). The P&T are appreciated. for use were modifi ed for 3 drugs. Committee took this action for medica- Magic Mouthwash will no longer be tion safety reasons. This continues the dispensed at Shands UF because there ◆ ADDED policy of not allowing the use of non- is no evidence that it works better than specifi c terms for mixtures that have a plain saline rinse. Clozapine Tablets traditionally been used. This action follows the banning of (generic by IVAX) Terms like “Magic Mouthwash” are the term “Butt Paste” several years Glutaraldehyde 0.6% Solution slang, jargon, or coined phrases for ago. Like Magic Mouthwash, Butt Paste (compounded) mixtures that have a specifi c purpose. is a nonspecifi c mixture of ingredients. Levofl oxacin In this instance, the “magic” is pain The “Butt Paste” mixture contained (Levaquin® by Ortho McNeil)* reduction in patients who have muco- Questran Light® (cholestyramine) in sitis of the mouth. Mucositis is a very Aquaphor®. The theory is that the cho- Ondansetron Tablets ® painful condition in patients receiving lestyramine binds bile acids that may (Zofran by GlaxoSmithKline) aggressive cytotoxic chemotherapy.
    [Show full text]
  • Pharmacy Manual Supplemental Policies, Procedures and Regulations
    Last revision date: 12.17.2020 Pharmacy Manual Supplemental Policies, Procedures and Regulations Prepared by: Elixir 800-361-4542 ELIXIRSOLUTIONS.COM 2181 E. Aurora Road, Suite 201 | Twinsburg, OH 44087 Copyright © 2020, Elixir. All rights reserved. Version 41 *This page was intentionally left blank* 1 Table of Contents PHARMACY MANUAL INTRODUCTION......................................................................................................................... 5 GENERAL INFORMATION ............................................................................................................................................. 5 PROPRIETARY AND CONFIDENTIAL .................................................................................................................. 5 ADVERTISING REQUESTS .............................................................................................................................. 6 CONTACT INFORMATION / WHERE TO GET HELP ...................................................................................................... 6 NETWORK ENROLLMENT FORM AND CREDENTIALING GUIDELINES ....................................................................... 6 APPLYING FOR PARTICIPATION ...................................................................................................................... 6 CREDENTIALING AND RECREDENTIALING GUIDELINES ....................................................................................... 7 PROVIDER AND MEMBER SERVICE STANDARDS .....................................................................................................
    [Show full text]
  • Epinephrine Auto-Injector
    ELIXIR; Epinephrine Auto-Injector FINAL DESIGN & PRODUCT SPECIFICATION REPORT DNH603_SEM2 Zoe Avgoustakis n8607912 CONTENTS 1. Introduction 2. Final Product Design 2.1 Description 2.2 Usability 2.3 QoI Table / Product Ecosystem 3. Value Proposition , 4. Design Justification 4.1 Mechanism 4.2 Form 4.3 Usability 5. Technical Documentation 5.1 Product Components 5.2 Product Function 5.3 Specifications 5.4 Standards 5.5 B.O.M Technical Drawings DNH603_16se2 : i-move project Epinephrine Auto-injector Zoe Avgoustakis n8607923 0.03mg Adrenaline 1. INTRODUCTION Over the course of this project, imm-you-nity has worked to provide innovative design solutions focused on interactive interfaces and devices to help people be more aware, in control and engaged with their health and wellness. The project aim was to design and develop a new consumer interactive product that would provide a distinct personal experience, improving the user’s management and relationship with their Health & Wellness. The project was specifically focused towards the user’s engagement with allergy conditions. Design investigation accounted for emerging technologies and how this could be applied to enhance the user’s management and interaction with severe allergies and anaphylaxis. Australia has one of the highest reported incidences of food allergies in the world with one in ten people forecasted to develop a food allergy throughout their lives. As those who obtain allergies become more and more prevalent, people are turning to technology for assitance of this issue. The client approached the team in endeavour to develop a product that could assist people with the management and treatment of severe allergy conditions of anaphylaxis.
    [Show full text]
  • 2020 PBD 5 Tier Formulary
    2020 Pharmacy Benefit Dimensions 5 Tier Drug Formulary The following information applies to most members enrolled in a Pharmacy Benefit Dimensions pharmacy plan. Note: If you are reading a printed version of this drug formulary, content may have been updated since it was last printed. For the most up-to-date information, please visit www.pbdrx.com. Drug Formulary Introduction • Generic drugs appear in lower case. Brand name drugs are capitalized. • Preferred generic drugs and a few select brand name drugs are assigned to Tier 1. In most instances, once a generic product is available for which there are no bioequivalence concerns, the brand product is removed from the formulary (not covered), and the generic product is assigned to Tier 1. Certain generic drugs may also be covered in a non-preferred tier when efficacy, safety, or cost factors suggest that better alternatives exist on the formulary. • Pharmacy Benefit Dimensions reserves the right to modify drug tiers as necessary. • Some medications are considered non-formulary (not covered). To obtain a medication that is non-formulary, your health care provider is encouraged to submit a Prior Authorization request for coverage through the exception process. If the request is approved, you will be responsible for the cost share associated with a non- preferred drug tier. • Certain self-funded employer groups may not follow this base formulary and certain exclusions may apply. Members in these pharmacy benefit management groups should refer to their summary plan description and/or their benefit administrator. Prior-Authorization Prior Authorization is required for certain medications. To obtain coverage for a medication requiring Prior Authorization, a Prior Authorization request for medical exception must be submitted by your health care provider and approved by Pharmacy Benefit Dimensions.
    [Show full text]